Patents by Inventor Robert Dean Dally

Robert Dean Dally has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 9776992
    Abstract: 1-Oxo-1,2-dihydroisoquinolin-7-yl-(5-substituted-thiophen-2-yl)-sulfonamide compounds, formulations containing those compounds, and their use as AICARFT inhibitors.
    Type: Grant
    Filed: November 24, 2015
    Date of Patent: October 3, 2017
    Assignee: Eli Lilly and Company
    Inventors: Harold Burns Brooks, Robert Dean Dally, Timothy Barrett Durham, Kevin Robert Fales, Kwame Frimpong, Jefferson Ray McCowan, Frank George Njoroge, Timothy Alan Shepherd, Chong Si, Kenneth Jeff Thrasher, James Lee Toth, Zhipei Wu
  • Publication number: 20170233378
    Abstract: 1-Oxo-1,2-dihydroisoquinolin-7-yl-(5-substituted-thiophen-2-yl)-sulfonamide compounds, formulations containing those compounds, and their use as AICARFT inhibitors.
    Type: Application
    Filed: November 24, 2015
    Publication date: August 17, 2017
    Applicant: Eli Lilly and Company
    Inventors: Harold Burns BROOKS, Robert Dean DALLY, Timothy Barrett DURHAM, Kevin Robert FALES, Kwame FRIMPONG, Jefferson Ray MCCOWAN, Frank George NJOROGE, Timothy Alan SHEPHERD, Chong SI, Kenneth Jeff THRASHER, James Lee TOTH, Zhipei WU
  • Patent number: 9156824
    Abstract: The present invention provides isoindolinone compounds, or a pharmaceutically acceptable salt thereof, that inhibit CDC7 and, therefore may be useful in treating cancer.
    Type: Grant
    Filed: March 7, 2014
    Date of Patent: October 13, 2015
    Assignee: Eli Lilly and Company
    Inventors: Robert Dean Dally, Timothy Andrew Woods
  • Publication number: 20140275121
    Abstract: The present invention provides isoindolinone compounds, or a pharmaceutically acceptable salt thereof, that inhibit CDC7 and, therefore may be useful in treating cancer.
    Type: Application
    Filed: March 7, 2014
    Publication date: September 18, 2014
    Applicant: Eli Lilly and Company
    Inventors: Robert Dean DALLY, Timothy Andrew WOODS
  • Patent number: 8217032
    Abstract: The present invention relates to a selective estrogen receptor modulator of formula I or Ia: (I) (Ia); or a pharmaceutical acid addition salt thereof; useful for treating vasomotor symptoms, in particular hot flashes, night sweats and other symptoms that affect women around menopause.
    Type: Grant
    Filed: June 23, 2011
    Date of Patent: July 10, 2012
    Assignee: Eli Lilly and Company
    Inventors: Robert Dean Dally, Jeffrey Alan Dodge, Scott Alan Frank, Ronald Jay Hinklin, Timothy Alan Shepherd, Owen Brendan Wallace
  • Patent number: 8148387
    Abstract: The present invention provides AKT and p70 S6 kinase inhibitors of the formula: The present invention also provides pharmaceutical compositions comprising compounds of Formula I, uses of compounds of Formula I and methods of using compounds of Formula I.
    Type: Grant
    Filed: November 3, 2009
    Date of Patent: April 3, 2012
    Assignee: Eli Lilly and Company
    Inventors: Timothy Alan Shepherd, Robert Dean Dally, Sajan Joseph
  • Publication number: 20120071490
    Abstract: The present invention provides p70 S6 kinase inhibitors of the formula: pharmaceutical formulations comprising them, and methods for their use.
    Type: Application
    Filed: November 30, 2011
    Publication date: March 22, 2012
    Applicant: ELI LILLY AND COMPANY
    Inventors: Robert Dean Dally, Jianping Huang, Sajan Joseph, Timothy Alan Shepherd, Christian L. Holst
  • Publication number: 20110281847
    Abstract: The present invention relates to a selective estrogen receptor modulator of formula I or Ia: (I) (Ia); or a pharmaceutical acid addition salt thereof; useful for treating vasomotor symptoms, in particular hot flashes, night sweats and other symptoms that affect women around menopause.
    Type: Application
    Filed: June 23, 2011
    Publication date: November 17, 2011
    Applicant: ELI LILLY AND COMPANY
    Inventors: Robert Dean Dally, Jeffrey Alan Dodge, Scott Alan Frank, Ronald Jay Hinklin, Timothy Alan Shepherd, Owen Brendan Wallace
  • Patent number: 7863310
    Abstract: The present invention provides kinase inhibitors of Formula I:
    Type: Grant
    Filed: January 21, 2005
    Date of Patent: January 4, 2011
    Assignee: Eli Lilly and Company
    Inventors: Rosanne Bonjouklian, Robert Dean Dally, Alfonso de Dios, Mirian Filadelfa del Prado Catalina, Carmen Dominguez-Fernandez, Carlos Jaramillo Aguado, Beatriz Lopez de Uralde-Garmendia, Timothy Alan Shepherd
  • Patent number: 7745438
    Abstract: The present invention provides BACE inhibitors of Formula (I); methods for their use and preparation, and intermediates useful for their preparation.
    Type: Grant
    Filed: September 20, 2005
    Date of Patent: June 29, 2010
    Assignee: Eli Lilly and Company
    Inventors: Howard Barff Broughton, Robert Dean Dally, Timothy Barrett Durham, Maria Rosario Gonzalez-Garcia, Patric James Hahn, Kenneth James Henry, Jr., Todd Jonathan Kohn, James Ray McCarthy, Timothy Alan Shepherd, Jon Andre Erickson, Ana Belen Bueno Melendo
  • Publication number: 20100120801
    Abstract: The present invention provides AKT and p70 S6 kinase inhibitors of the formula: The present invention also provides pharmaceutical compositions comprising compounds of Formula I, uses of compounds of Formula I and methods of using compounds of Formula I.
    Type: Application
    Filed: November 3, 2009
    Publication date: May 13, 2010
    Inventors: Timothy Alan Shepherd, Robert Dean Dally, Sajan Joseph
  • Patent number: 7585977
    Abstract: The present invention relates to a selective estrogen receptor modulator of formula I or a pharmaceutical acid addition salt thereof; useful, e.g., for treating endometriosis and/or uterine leiomyoma/leiomyomata.
    Type: Grant
    Filed: April 9, 2008
    Date of Patent: September 8, 2009
    Assignee: Eli Lilly and Company
    Inventors: Robert Dean Dally, Jeffrey Alan Dodge, Scott Alan Frank, Scott Alan Jones, Timothy Alan Shepherd, Owen Brendan Wallace, Kin Chlu Fong, Conrad Wilson Hummel, George Sal Lewis
  • Publication number: 20090163714
    Abstract: The present invention provides p70 S6 kinase inhibitors of the formula: pharmaceutical formulations comprising them, and methods for their use.
    Type: Application
    Filed: March 2, 2009
    Publication date: June 25, 2009
    Inventors: Robert Dean Dally, Jianping Huang, Sajan Joseph, Timothy Alan Shepherd, Christian L. Holst
  • Publication number: 20090023917
    Abstract: The present invention relates to a selective estrogen receptor modulator of formula I or Ia: (I) (Ia); or a pharmaceutical acid addition salt thereof; useful for treating vasomotor symptoms, in particular hot flashes, night sweats and other symptoms that affect women around menopause.
    Type: Application
    Filed: January 18, 2005
    Publication date: January 22, 2009
    Applicant: Eli Lilly and Company
    Inventors: Robert Dean Dally, Jeffrey Alan Dodge, Scott Alan Frank, Ronald Jay Hinklin, Timothy Alan Shepherd, Owen Brendan Wallace
  • Publication number: 20080227839
    Abstract: The present invention provides kinase inhibitors of Formula I:
    Type: Application
    Filed: January 21, 2005
    Publication date: September 18, 2008
    Inventors: Rosanne Bonjouklian, Robert Dean Dally, Alfonso de Dios, Mirian Filadelfa del Prado Catalina, Carmen Dominguez-Fernandez, Carlos Jaramillo Aguado, Beatriz Lopez de Uralde-Garmendia, Carlos Montero Salgado, Timothy Alan Shepherd
  • Publication number: 20080214612
    Abstract: The present invention relates to a selective estrogen receptor modulator of formula I or a pharmaceutical acid addition salt thereof; useful, e.g., for treating endometriosis and/or uterine leiomyoma/leiomyomata.
    Type: Application
    Filed: April 9, 2008
    Publication date: September 4, 2008
    Inventors: Robert Dean Dally, Jeffrey Alan Dodge, Scott Alan Frank, Scott Alan Jones, Timothy Alan Shepherd, Owen Brendan Wallace, Kin Chlu Fong, Conrad Wilson Hummel, George Sal Lewis
  • Patent number: 7320995
    Abstract: The present invention provides kinase inhibitors of Formula I: wherein W represents inter alia imidazol, oxazol, pyrazol, thiazol as triazol, which are substituted by phenyl or thienyl.
    Type: Grant
    Filed: July 31, 2003
    Date of Patent: January 22, 2008
    Assignee: Eli Lilly and Company
    Inventors: Rosanne Bonjouklian, Jose Eugenio De Diego Gomez, Alfonso De Dios, Chafiq Hamdouchi Hamdouchi, Tiecho Li, Beatriz Lopez De Uralde Garmendia, Michal Vieth, Jeremy Schulenberg York, Robert Dean Dally, Miriam Filadelfa Del Prado Catalina, Carlos Jaramillo Aguado, Luisa Maria Martin-Cabrejas, Carlos Montero Salgado, Sheila Pleite Selgas, Concepcion Sanchez-Martinez, Timothy Alan Shepherd, James Howard Wikel